The authors report the case of a 41-year-old woman who developed an acute graft-versus-host disease following bone marrow transplantation for post-polycythemic myeloid metaplasia; liver, cutaneous and intestinal lesions were present, associated, with a severe protein-losing enteropathy. Symptoms, diagnostic procedures and therapy of intestinal graft-versus-host disease are reviewed. The intestinal clearance of alpha-1 antitrypsin was particularly useful to assess the response to medial treatment, which induced a complete remission.
Thromboembolism represents a severe complication of inflammatory bowel disease occurring in young patient, with active disease. Deep venous thrombosis and pulmonary embolism are the most frequent thromboembolism manifestations. Arterial complications and unusual sites for thromboembolism are more rare. Overall, inflammatory bowel disease is a real prothrombotic state as almost all parameters of coagulation are enhanced. Anticoagulation during the episode of thromboembolism is mandatory, and sometimes may ameliorate the course of inflammatory bowel disease.
52 patients with refractory or relapsed acute myeloid leukaemia (AML) were randomly assigned to receive a combination of high‐dose cytosine arabinoside (HD Ara‐C), 3 g/m 2 /d and either mitoxantrone (MTX), 7 mg/m 2 /d (5 mg if older than 60 yr) or m‐amsacrine (AMSA), 120 mg/m 2 /d (90 mg if older than 60 yr) for 5 d. The overall response rate was 50% and did not differ significantly in the two groups (46% for AMSA and 56% for MTX, p = 0.415). The median survival was 11 months (8 months for AMSA and 12 months for MTX, p = 0.326) and the median duration of complete remission (CR) was 11 months for AMSA and 12 months for MTX (p = 0.643). In relapsed patients, the only significant predictive factor for obtaining a complete response was the length of first complete remission. Patients with a first CR shorter than 6 months had a CR rate of 36% while it was 65% if the first CR lasted more than 6 months (p = 0.03). Severe (WHO grade III‐IV) gastro‐intestinal toxicity was more frequent in the AMSA group (27% vs 4%, p = 0.021). Treatment‐related death occurred in 4 patients in the AMSA group and in 2 patients in the MTX group (p = 0.097). We conclude that neither of these two treatment modalities was shown to be superior in terms of CR rate and survival, with a better tolerance for MTX.
We report 2 cases of severe nontyphoidal salmonellosis (Salmonella enteritidis), occurring 4 and 5 weeks after starting a treatment with Omeprazole (20 mg a day). No other member of the families was sick, and none of the 2 patients took any meals outside home during the two weeks preceding the first symptoms. Gastric hypochlorhydria is a major risk factor for Salmonella enteritidis, and several cases of severe infection have been described with this condition. After a review of the literature we conclude that patients with diminished gastric acid run an increased risk of developing Salmonella infection and often with a more serious clinical course.
Surveillance for early detection of hepatocarcinoma (HCC) in patients with cirrhosis is widely accepted. In a cohort of 141 patients with cirrhosis collected during the year 1995, we conducted a surveillance program by performing liver ultrasonography and blood alpha-foetoprotein measurement every 6 months. The median follow-up was 34 months. This study addressed to two questions: the compliance to the surveillance schedule according to the aetiology of cirrhosis and the results in terms of emergence of HCC and outcome. Aetiology of cirrhosis was alcohol-induced in 86 (61%), HCV-related in 30 (21%) and from other origins in 25 (18%). Compliance to the program schedule was good in patients with HCV-related cirrhosis (29/30--97%) and patients with cirrhosis of "other origins" (20/25--80%) but was poor in patients with alcoholic cirrhosis (45/86--52%). The lack of compliance was significantly linked to the failure to achieve alcohol abstinence. During follow-up, 6 HCC lesions were observed in 6 male patients with median age of 68 years. All 6 HCC were single nodule, less than 4 cm and accessible to percutaneous acetic acid injection. Nevertheless, the outcome was disappointing, four patients dying 3-15 months later (median: 8 months), two of them with extensive HCC. One of the two patients still alive developed extensive HCC, 36 months after percutaneous acetic acid injection.
